Moderna awarded tender for COVID-19 vaccine

Moderna Secures European Contract For Covid-19 Vaccine
Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to enhance healthcare delivery.
Moderna Awarded Tender for the Supply of Its mRNA COVID-19 Vaccine in the European Union
The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats
Moderna Receives EU Tender Order for Covid-19 Vaccine
Moderna on Friday said it received approval for supplying its Spikevax Covid-19 vaccine to the European Union, Norway and North Macedonia following a tender process. Under the agreement, 17 participating countries could order an updated version of the biotech company's mRNA Covid-19 vaccine for up to four years.
Moderna awarded tender for COVID-19 vaccine in EU, Norway and North Macedonia
Moderna (MRNA) announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine in the European Union, Norway and North
Moderna Retains Retail Support With European COVID-19 Vaccine Tender Win, Stock Hits 2-Week High
Shares of Moderna Inc. climbed nearly 1% on Friday, reaching levels last seen on Jan. 10, as retail sentiment turned increasingly positive following the company’s announcement of a new vaccine tender agreement.
Moderna secures EU deal for mRNA COVID-19 vaccine supply
The press release also contained forward-looking statements, cautioning that these are not guarantees and are subject to risks, uncertainties, and other factors that could cause actual results to differ from expectations.
Moderna extends gains as EU offers COVID vaccine contract
Following four straight sessions of gains, Moderna (NASDAQ:MRNA) shares continued to trade higher in the premarket on Friday after the company received a tender to supply its COVID-19 vaccine in the EU,
As bird flu becomes a growing threat, Moderna is awarded $590M to develop mRNA pandemic influenza vaccines
No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...
From Covid to Norovirus: Moderna’s mRNA Tech Takes on Stomach Flu
The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...
bovnews3d
MRNA Unveiled: The Shocking Truth Behind Moderna Inc’s Latest Stock Movements
Moderna Inc (MRNA) stock saw a modest uptick, ending the day at $38.5 which represents a slight increase of $2.61 or 7.27% from the prior close of $35.89. The stock opened at $36.35 and touched a low ...
Why Moderna Stock Jumped Over 20% This Week
Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market ...
Moderna awarded $590M to help accelerate development of mRNA-based bird flu vaccine: HHS
Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...
Moderna spikes as Oracle’s Larry Ellison touts AI-driven mRNA vaccines
Chairman Larry Ellison highlighted the AI's potential in the development of mRNA-based cancer vaccines. Read more here.
GlobalData on MSN5d
HHS awards $590m to Moderna for mRNA ‘flu vax development
Moderna is set to receive $590m in funding from the HHS to expedite the development of mRNA-based pandemic influenza vaccines ...
Is Moderna Stock a Buy?
While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...
Moderna Gets $590 Million in Federal Funding for Bird Flu Vaccine
The current public-health risk is low, but the CDC is working with states to monitor people with animal exposure.
Managed Healthcare Executive5d
Moderna Awarded $590 Million for Bird Flu Vaccine Development
The Department of Health and Human Services (HHS) will award roughly $590 million to Moderna to accelerate the development of ...
pulmonologyadvisor2d
Moderna Provides Update on Norovirus Vaccine Candidate
Moderna provided an update on the status of its trial investigating a vaccine candidate for norovirus in a company statement on Monday.